The Impact of Certain Factors on Survival Rate in Patients with Primary Biliary Cholangitis Abedi Rusul F. ahmedjalal07729@gmail.com Baghdad Iraq 03 09 2026 09092026 Introduction

Primary biliary cholangitis (PBC) is a one of most common rare progressive autoimmune liver disease that it is affected in middle and involved persistent chronic inflammation of interlobular bile duct which can lead to liver damage. If it is left untreated, PBC can lead to cirrhosis, decompensation and death. It requires novel therapies or liver transplantation[1] [2] [3]. PBC was formerly known as Primary Biliary Cirrhosis, but the designation was around 2015, because cirrhosis was not a necessary condition for the diagnosis of this disease [4].

PBC is classified into four stages: Stage I (portal stage) involves portal inflammation with granulomatous destruction of bile ducts; Stage II (periportal stage) shows periportal fibrosis, Stage III (septal stage) demonstrates bridging fibrosis, and Stage IV represents cirrhosis [5] [6]. The Biochemical markers play a central role in the diagnosis, monitoring, and prognostication of PBC. In PBC, patients have increased serum alkaline phosphatase enzyme (ALP), positive antimicrobial antibody (AMA) [7] in addition to slight to moderate elevation in aminotransferase enzymes, alanine aminotransferase (ALP), aspartate aminotransferase (AST) [8].

As a disease progress hyperbilirubinemia occur and significant hyperbilirubinemia indicates to advanced disease, and regard as reliable predictors of adverse outcome in PBC, when hyperbilirubinemia co-occur with thrombocytopenia, reduce albumin levels, and elevated international normalized rate (INR), it is indicated to development decompensated cirrhosis [9].

The relationship between these biochemical markers and survival rate is complex and clinically important, several prognostic models integrate biochemical markers to predict outcome including Mayo risk score, albumin-bilirubin (ALBI) score, UK-PBC and GLOBE scores [10]. The UK-PBC score includes measurements of AST, ALT, ALP, bilirubin at 12 months and albumin, platelets at baseline to estimate risk of liver transplant and liver-related death within 5,10, and 15 years [11], and GLOBE score includes age, ALP, bilirubin, albumin and platelets to estimate liver transplantation free survival at 3,5,10, and 15 years [12].

PBC has early and advanced stages of progression. Physical examination in early stages is usually normal, although presence hepatomegaly, xanthoma. Jaundice is late finding of liver advanced disease in addition to many sings such as ascites, edema, spiders angiomata may be found in setting of portal hypertension [13]. The death is commonly due to complications of the disease or liver failure. PBC is a progress in most cases but the rate of progression varies greatly among individual patients asymptomatic have substantially longer life expectancies than symptomatic ones, but their survival is still less than the healthy individual. Median survival rate of asymptomatic patients was 10 to 16 years in the two large cohorts followed for up to 24 years and median survival rate of symptomatic patients is approximately 7 years [14]. Liver transplant (LT) is the only treatment option for end stage liver disease [15]. This study aims to determine the impact of certain factors such as sex, age, laboratory variables as AST, ALP liver enzymes, bilirubin, albumin, copper, prothrombin time, platelets count, cholesterol, triglyceride, ascites, hepatomegaly, spiders and edema on survival rate in PBC. Also, the survival rate between asymptomatic and symptomatic patients was studied.

Materials and methods

2.1 Data collection

The patient’s population for development and testing survival rate in PBC models, consist of patients with primary biliary cirrhosis recently known as primary biliary cholangitis (PBC) those who were at Mayo Clinic between January 1974 to May 1984 which met the biochemical and histological criteria of PBC. Total patients sample were 424 patients qualified for the randomized placebo-controlled trial testing the drug D-penicillamine,112 patients didn’t join with study but agree to record basic metrics, 312 patients took part in the trial and have mostly comprehensive data [16]. Data of patients consist of 17 variables in addition to ID patients, time and status, the demographic variables as shown in Table 1, clinical laboratory variables shown in Table 2.

2 Clinical laboratory variables

NO. Variable name Type Description
1 sex Categorical M (male) or F (female)
2 Age Integer days
3 time Integer (days) number of days between registration and the earlier of death, transplantation, or study analysis time in July 1986
4 Status Categorical Status of the patient:1= C(censored),2=CL (censored due to liver transplantation), or 0=D (dead)
5 drug Categorical type of drug D-penicillamine or placebo
6 Ascites Categorical Existence of fluid in abdomen, 0 (No) or 1 (Yes)
7 Hepatomegaly Categorical Existence of enlarge liver, 0 (No) or 1 (Yes)
8 Spiders Categorical Existence of blood vessels malformations in skin ,0 (No) or 1 (Yes)
9 Edema Categorical Existence of fluid in body tissues,0=no edema and no diuretics therapy,0.5=presence edema without diuretics or edema resolved diuretics,1=edema despite diuretics therapy.

No. Variable Name
1 Bilirubin: serum bilirubin in [mg/dl]
2 Albumin: serum albumin in [gm/dl]
3 Copper: urine copper in [µg /day]
4 Alk Phos: serum alkaline phosphatase in [U/liter]
5 AST: serum aspartate aminotransferase in [U/liter]
6 Cholesterol: serum cholesterol in [mg/dl]
7 Triglycerides: serum triglycerides in [mg/dl]
8 Platelets: platelets per cubic [ml/1000]
9 Prothrombin: prothrombin time in seconds [s] to evaluate the extrinsic pathway of coagulation
10 Stage: histologist stage of disease (1, 2, 3, 4)

2.2 Statistical analysis

Study data are concerned with knowing the probability of the PBC patient remaining before the appearance of a certain event (liver transplantation or death), where the result of the disease is linked to the number of days spent by the patient in the days from the beginning of the diagnosis until the appearance of an outcome event, when outcome takes three cases, namely (0 censored, 1 censored due to liver transplantation, and 2 dead). From the nature of the data, the appropriate statistical method for analysis is (cox-regression) and Kaplan-Meier [17] [18], all results from this study we depended on python 3.13 program to import data and clean it from missing and outlier values.

2.2.1 Cox-Regression analysis:

Cox-regression is characterized by a set of advantages in statistical analysis, including are:

Don't need to specify the shape of the latency distribution (non-parametric)

We can apply in Quantitative and categorical variables

Very useful for identifying the factors that affect survival the most

The 17 independent variables for the Cox model as in a multiple regression, the P-value was used as a criterion to decide whether a variable was statistically significant (P ≤ 0.05) by Z-statistic and also to determine which variable is most informative other criteria such as OR and Hazard rate (HR); if HR>1 this mean variable(feature) increase danger of disease with ratio (HR-1)*100; and if HR<1 feature decrease with ratio(1-HR)*100.

To drawing the curves of the survival function according to each descriptive variable by Kaplan-Meier analysis.

2.2.2 Kaplan–Meier analysis:

Kaplan–Meier analysis (or Kaplan–Meier estimates) are a statistical tool used in Survival Analysis to represent the probability that a group of individuals will survive (or that a particular event such as disease relapse or organ failure will not occur) over time. Kaplan–Meier curve: Purpose: Estimates the Survival Function and shows the probability of survival at each point in time. Input data: Depends on survival times considering "censored" cases, i.e. individuals who did not have the event until the end of the follow-up. Instructions: Whenever an "event" occurs (such as death or treatment failure), the Step Function curve drops abruptly. Times when an event does not occur remain stable (horizontal line). Comparison between groups: More than one Kaplan–Meier curve can be compared using the Log-rank test (chi-square criteria) to see if there is a substantial difference between the groups. Graphic Representation: Horizontal axis (X) = time. Vertical axis (Y) = probability of survival, the curve starts at a value of 1 (100% survival) and decreases as events occur.

 Results

3.1 Descriptive statistics

Overall, 312 patients with PBC were included, their mean age was 50.19 (26.28-78.44) years, among them 276 were female and 36 were male. Also average of time variable (survival rate) in sample was 2006.362 days, it ranges from (41-4556) days. All variables (features) are shown in as following Tables 3 to 5.

3 Some Descriptive statistics of variables

Variables Mean ± SD Min Max International Standards(normal ranges)
Time(days) 2006.362 ± 1123.281 41 4556
Age 50.019 ± 10.581 26.278 78.439
Bilirubin 2.676 ± 3.151 0.3 28 0.1 – 1.2 mg/dL
Cholesterol 201.247 ± 98.069 100 636 < 200 mg/dL
Albumin 3.935 ± 1.035 2.54 8.9 3.5 – 5 g/dL
Copper 79.648 ± 85.338 40 588 ≤ 30 µg/day
ALP 145.981 ± 115.028 30 761 40 – 129 U/L
AST 48.509 ± 36.370 1.91 238 8 – 48 U/L
Triglycerides 124.702 ± 61.927 33 598 <150 mg/dL
Platelets count 295.063 ± 96.888 97 650 140 – 440 ×10⁹/L
Prothrombin time 11.343 ± 1.645 9 17.1 9.5 – 12.5 seconds

Normal ranges according to internationally recognized clinical laboratory standards such as Mayo Clinic Laboratories and Merck Manual (MSD).

Feature categorical count feature categorical count
Sex Male 36 Edema Level_0 263
Female 276 Level_0.5 29
Drug D-penicillin 158 Level_1 20
Placebo 154 Stage 1 16
Ascites No 288 2 67
Yes 24 3 120
Hepatomegaly No 160 4 109
Yes 152
Spiders No 222
Yes 90

Variable Category Censored Censored due to transplantation Dead P-value Sig.
Drug Penicillamine 83 (49.4%) 10 (52.6%) 65 (52.0%) 0.8935 ns
Drug placebo 85 (50.6%) 9 (47.4%) 60 (48.0%) 0.8935 ns
Sex Female 157 (93.5%) 16 (84.2%) 103 (82.4%) 0.0115 *
Sex Male 11 (6.5%) 3 (15.8%) 22 (17.6%) 0.0115 *
Ascites No 166 (98.8%) 19 (100.0%) 102 (81.6%) <0.00001 ***
Ascites Yes 2 (1.2%) 0 (0.0%) 23 (18.4%) <0.00001 ***
Hepatomegaly No 108 (64.3%) 7 (36.8%) 37 (29.6%) <0.00001 ***
Hepatomegaly Yes 60 (35.7%) 12 (63.2%) 88 (70.4%) <0.00001 ***
Spiders No 134 (79.8%) 14 (73.7%) 73 (58.4%) 0.0004 ***
Spiders Yes 34 (20.2%) 5 (26.3%) 52 (41.6%) 0.0004 ***
Edema Level_0 157 (93.5%) 17 (89.5%) 89 (71.2%) <0.00001 ***
Edema Level_0.5 10 (6.0%) 2 (10.5%) 17 (13.6%) <0.00001 ***
Edema Level_1 1 (0.6%) 0 (0.0%) 19 (15.2%) <0.00001 ***
Stage 1 15 (8.9%) 0 (0.0%) 1 (0.8%) <0.00001*** ***
Stage 2 48 (28.6%) 3 (15.8%) 16 (12.8%) <0.00001 ***
Stage 3 69 (41.1%) 8 (42.1%) 43 (34.4%) <0.00001 ***
Stage 4 36 (21.4%) 8 (42.1%) 65 (52.0%) <0.00001 ***

In Table (5) there is high significant difference in the number of patients with symptoms (ascites, hepatomegaly, spiders and edema) for each of three groups (censored, censored due to transplantation, dead), we see absence of ascites and edema level 1 in transplant group. The incidence of these symptoms in liver transplant group is low compared with censored and dead group. For example: transplant patients with hepatomegaly are 12(63.2%), spiders 5(26.3%), edema level (0.5) 2(10.5%). Also, incidence of patients with advanced histological stage (3,4) is 8(42.1%) patients it is consider is low compared to the censored and dead group. in Table (6) there is high significant difference in all laboratory variables among three groups, the bilirubin is slightly elevated in transplant group it is value 3.13, albumin 5.05 is high compared with other two groups, AST within normal range in transplant group but ALP is slightly elevated.

6 Comparison between clinical laboratory variables under type of status

Variable Censored Censored due to transplantation Dead p-value Sig.
Age 48.62 ± 10.49 41.18 ± 6.06 53.24 ± 10.11 0.0000 ***
Bilirubin 1.50 ± 1.75 3.13 ± 2.02 4.18 ± 4.00 0.0000 ***
Cholesterol 187.46 ± 66.28 241.84 ± 62.61 293.48 ± 105.49 0.0000 ***
Albumin 3.63 ± 0.33 5.05 ± 1.53 4.17 ± 1.35 0.0003 ***
Copper 66.80 ± 56.93 124.00 ± 100.08 135.11 ± 98.16 0.0000 ***
ALP 127.25 ± 69.21 146.74 ± 62.30 193.50 ± 153.70 0.0059 **
AST 34.65 ± 21.92 45.91 ± 29.83 67.53 ± 43.77 0.0000 ***
Triglycerides 113.09 ± 45.92 133.46 ± 68.59 138.97 ± 75.47 0.0055 **
Platelets count 272.37 ± 88.73 298.84 ± 79.60 324.98 ± 102.07 0.0001 ***
Prothrombin time 10.38 ± 0.85 10.37 ± 0.59 12.78 ± 1.51 0.0000 ***

3.2 Cox-Regression analysis

Univariate cox-regression analyses showed that presence disease symptoms such as (Ascites_(yes),Hepatomegaly(yes), Spiders_yes, Edema level_0.05) advanced histological stage (3,4),Prothrombin time, Bilirubin ,age, sex-male, Copper, AST, Triglycerides, Cholesterol) are high statistical significant (P-value<0.0001) and have risk factors for death and diminished survival rate, while variables (sex female, stage1,2, spiders_ no, Hepatomegaly(No),edema no, ascites_(no),hypoalbuminemia, thrombocytopenia are statistical significant but Hazard risk(HR) are Protective , as for the variables as (drug-penicillamine ,ALP, drug-placebo) are not significant for death (p-value>0.05) see following Table 7.

Table ( 7 ): Results of Cox-regression analysis

Variable Original variable Coef. HR p-value Interpretation
Ascites Yes ascites 2.053 7.790 5.332E-18 Risk factor
Hepatomegaly Yes Hepatomegaly 1.186 3.275 1.955E-09 Risk factor
Stage_4 stage 1.185 3.269 5.797E-11 Risk factor
Spiders Yes spiders 0.974 2.649 1.134E-07 Risk factor
Edma_0.5 Edma 0.686 1.986 8.667E-03 Risk factor
Sex male sex 0.484 1.622 4.075E-02 Risk factor
Prothrombin time Prothrombin time 0.380 1.462 1.208E-12 Risk factor
Stage_3 stage 0.280 1.323 1.378E-02 Risk factor
Bilirubin Bilirubin 0.149 1.161 2.579E-30 Risk factor
drug-penicillamine drug 0.057 1.059 7.494E-01 Not significant
Age age 0.040 1.041 5.651E-06 Risk factor
Copper copper 0.007 1.007 2.009E-18 Risk factor
AST AST 0.006 1.006 4.412E-08 Risk factor
Triglycerides Triglycerides 0.004 1.004 2.732E-04 Risk factor
Cholesterol Cholesterol 0.001 1.001 1.331E-03 Risk factor
ALP ALP 0.000 1.000 1.098E-01 Not significant
Thrombocytopenia platelet -0.003 0.997 2.372E-03 Protective
drug placebo drug -0.057 0.944 7.494E-01 Not significant
Sex female sex -0.484 0.616 4.075E-02 Protective
Stage_2 stage -0.870 0.419 1.192E-03 Protective
Spiders No spiders -0.974 0.377 1.134E-07 Protective
Hepatomegaly No Hepatomegaly -1.186 0.305 1.955E-09 Protective
Edema_0.0 Edema -1.388 0.250 3.054E-12 Protective
Hypoalbuminia albumin -1.796 0.166 9.835E-18 Protective
Ascites No ascites -2.053 0.128 5.332E-18 Protective
Stage_1 stage -2.378 0.093 1.794E-02 Protective

3.3 Kaplan-Meier analysis

Using Kaplan-Meier analysis for the data to diagnostic the time(days) and survival probability for each categorical variable (see Table 8).

Table (8) : Survival probability according four times

Variable Group Event Time Survival prob. Max (time) Median Survival
Sex Female 3853 0.39 4556 3428
Male 4191 0.206 4459 2386
Drug D-penicillamine 4191 0.319 4556 3282
placebo 3853 0.361 4523 3428
Stage 4 3762 0.187 4523 1682
3 4191 0.330 4500 3428
2 4079 0.397 4556 4079
1 2386 0.909 4459 ----
Edema Level_1 3428 0.000 3428 264
Level_0 4191 0.375 4556 3584
Level_0.5 3282 0.316 4232 1576
Hepatomegaly Yes 4191 0.159 4523 2256
No 3853 0.565 4556 ----
Spiders Yes 3762 0.149 4500 1847
No 4191 0.403 4556 3839
Ascites yes 3222 0.000 3222 388
No 4191 0.377 4556 3584

From the results in Table (8), there are two times according to each variable, the first of these times is event (time) represents the time of the appearance of the event (death) under study with a certain probability while Max (time) represents the last possible time of the event (death) to occur, which is always less than or equal to the continuation of the examination for the patients in the study (4556 days), for example in sex (female) the first time of death is 3853 day and max time is 4556 with survival probability 39%, while median survival is 3428 days.

The patient's survival probability varies according to the disease status such as sex, histological stage and disease symptom, the highest probability of survival is 0.91 in patients with first histological stage of disease and the first time of death (2386) while the lowest probability of survival is (0.000) for patients with presence (Edema level 1 and Ascites) and first time of event (death) 3428 ,3222 day respectively. and the median survival for edema 1 and ascites is 264 ,388 day respectively, survival decreasing according to time from disease detection until the end of the period; as shown in column (3) and column (4) of the table, and this can be observed through the Kaplan-Meier curves shown in the following figures:

Fig.(g): Survivals probability curve of histological stage

From the previous graphs it can be seen that the decreases in the lines represent events (deaths or failures of the event). Every plan line means that an event has occurred to an individual. Plane distances also mean that during that period no new events occurred (it continued to remain constant). Also, higher curve means a higher probability of long-term survival compared to low curves, and a decrease rate can be taken advantage of when the level is less than the median probability (0.50), for one curve faster than the other curve, indicating that this group has a lower survival rate or more early mortality.

Typically, not depend only curves diagnostic in such an analysis, but depend on statistical test such as a log-rank test is performed to ascertain whether the difference between the two curves is statistically significant or not (see Table (9)).

Table (9 ): Comparison between Variables Level according Chi-square test

Variables Chi-square p-value
Drug (D-penicillin vs placebo) 0.120814 0.728154
Sex (male vs female) 4.850086 0.027645
Histological stages (1,2,3,4) 58.34948 1.32E-12
Edema (0,0.5,1) 112.2748 4.17E-25
Spiders (0 vs 1) 28.37678 9.99E-08
Hepatomegaly (0 vs 1) 43.61176 4E-11
Ascites (0 vs 1) 87.67252 7.72E-21

From Table (9), it can be noted that the type of drug isn’t significant on survival. (p-value=0.728>0.05), but all other variables levels (histological stage, edema, spiders, hepatomegaly, and ascites) are significant differences in their impact on survival rate (p-value<0.001) only sex levels are low significant differences on survival (p-value<0.05).

Discussion

PBC is slowly progressive disease with natural history from 10-15 years that lead to end stage liver disease and high risk cases can progress to decompensated cirrhosis and death [19] [20],the study found that the symptoms of the disease such as (ascites, hepatomegaly, edema and spiders) are high risk factor of death and diminished survival rate and this consistent with the results previous studies [21] that show the (ascites, hepatomegaly) as important predictors of diminished survival rate. ascites is a one of major complications of liver cirrhosis and patients with ascites have lower survival rate as the disease progresses, therefore survival at 10-years after diagnosis 52% [22].

Also results of our study shows that the histological stages as stage 3 (portal bile stasis) and stage 4 (advanced fibrosis) are high risk factors of death and diminished survival rate that is consistent with study of Martini [23] which concluded that the advanced fibrosis and portal bile stasis are risk factors for diminished survival rate in PBC patients.

The older age plays central in decreasing survival rate according to findings study that conducted by [24] showed the prevalence of PBC increase with age and it is identified in middle age individual (40-60) years.

And sex-male is risk factor of death and decline survival rate as shown in the results of current study and this is consistent with pervious study by [25], which concluded that the sex male is independent poor prognostic factor for death and transplantation in PBC, because PBC is advanced in male and associated with greater progression to cirrhosis and hepatocellular carcinoma (HCC),

The clinical laboratory markers play important role in diagnosis and predication of PBC outcome, results of the current study found that each of the following laboratory parameters such as bilirubin, prothrombin time, AST, cholesterol, triglyceride and, copper are risk factors for death in PBC, the bilirubin level is high risk factor of death, this consistent with previous study [26] which proved that the hyperbilirubinemia independent markers for death and impaired chance of survival. also, AST, prothrombin time and presence spiders in current study are high risk factor for of death and this consistent with results of study [27]. In pervious investigation [28] which show the prolonged elevation in AST, total bilirubin, ALP, fibrosis score 4, (APRI) may increase risk of negative outcomes in PBC patients. Other investigation [29] revealed that the AST, bilirubin, albumin, ascites, organomegaly, and cirrhosis stage 4 are significantly impact on PBC patients’ survival rate. also, hyperlipidemia is main complications of PBC, our study shows high cholesterol, triglyceride levels are risk factors of death and diminished survival rate, Hypercholesterolemia is risk factor of death because cholesterol led to development ductopenia in early stages of PBC according to previous study [30].

The results of current study showed that some variables such as (sex-female, platelets, albumin, histological stage 1,2 and absence of ascites, edema, hepatomegaly and spiders) are statically significant risk of death but hazard risk (HR) are protective, this means that they could potentially high-risk factor of death in future and that it needs to be monitored to prevent the situation from worsening. Thrombocytopenia lower platelets count in current study has protective hazard risk for death, pervious study by [31] show that the platelets are prognostic factor and impaired survival rate in PBC. and albumin as protective hazard risk for death, hypoalbuminemia is significant risk factor for decline survival rate [32].

Other some variables as drug-D-penicillamine, drug-placebo and alkaline phosphatase (ALP) are not significant of death. ALP is not risking factor for death that is inconsistent with pervious study [32] which show higher ALP levels associated with an increased risk of disease progression. according Table (6) in present study use Kaplan -Meier analysis (median survival) with days And survival probability for each categorical variable, since the sex-male is a risk factor of death, the probability of survival rate for male is 20%, with median survival 2386 day, while in female survival probability 39% with median survival probability3428 day.as shown in fig(a), there is low significant difference between sex-male and female in the effect on survival rate according Chi-square test Table (7). also, patients with histological stages (3,4) have lower survival probability 33%,18% with lower median survival rate is approximately 3428 day and 1682 day respectively compared to histological stage (1,2) as shown in fig(G), there is high significant difference between stages (1,2,3,4) for risk factor of death. according Chi-square test (Table 9)

Patients suffering from (edema, hepatomegaly, spiders and ascites) have lower survival probability and median survival in days than patients who do not have these symptoms, as shown in figures (c,d,e,f), there are high significant differences between presence or absence (edema, hepatomegaly, spiders, ascites) in it is effect on survival rate according Chi-square test Table (9).

From this we conclude that patients with symptomatic patients have lower survival rate than asymptomatic patients, this like previous study [14] which show asymptomatic patients have survival rate 10-16 years and symptomatic patients is approximately 7 years, also study by [23] show the presence of these symptoms increase risk of disease.

There is high significant difference in all clinical laboratory variables and symptoms of disease as (ascites, hepatomegaly, edema, spiders) among three patients’ groups: censored, transplant and censored, dead), pervious study [33] which show there was presence significant difference in some laboratory variables as (bilirubin, albumin, prothrombin time) between UDCA treated patients with good outcome group and transplant or dead group. but ALP enzyme was not significant different. Other study [29] found the significant different between bilirubin, albumin, mayo risk score among alive patients and dead or transplant patients also cirrhosis stage 4, ascites and jaundice high in dead patients’ groups.

Transplant patients in current study have AST within normal range but bilirubin and ALP are slightly elevated after liver transplant, and incidence of transplant patients with histological stage (3,4) is 42.1%. Findings study of Carols et al [34] showed that 13 from 52 surviving patients have abnormalities liver functions tests at the time of last follow up, though none were jaundiced. In pervious study that show that the last -follow up for all patients hold marked symptomatic improvement compared with their pretransplant condition and 91% of patients had normal hepatic laboratory markers including serum ALP, bilirubin, ALT ,41 from 60 patients had near normal liver histological appearance, 5 patients had histological feature of florid duct lesion, although normal hepatic biochemical value this suggest recurrent of PBC after transplantation.

 Conclusion

This study concluded that age, sex-male, ascites, hepatomegaly, spiders, edema, bilirubin, cholesterol, triglyceride, aminotransferase level, copper, advanced histological stages are significant impact on survival rate in PBC, also mean survival rate lower in symptomatic patients compared with asymptomatic patients.

30 5 9 614-618 36 2024 10.7416/AI.2024.2629 10.7416/AI.2024.2629 Pensieri F Pigozzi MG Pintossi Es Plebani F Poisa P Ricci C Rinaldis G Skiti H Tabaglio E Zanotti F Zubani S Donato Francesco Graciella Pigozzi Marie Colarieti Giulia Festa Marco Tabaglio Erminio Annali di Igiene Medicina Preventiva e di Comunità Why are rare diseases underdiagnosed? A clinical management study on detection of primary biliary cholangitis in primary care 19 18 9 1580 13 2024 10.3390/CELLS13181580 10.3390/CELLS13181580 Fiorucci S ; Urbani G ; Di Giorgio Biagioli C ; Distrutti M ; Fiorucci Stefano Urbani Ginevra Giorgio Cristina Biagioli Michele Distrutti Eleonora Cells 2024, Vol. 13, Page 1580 Current Landscape and Evolving Therapies for Primary Biliary Cholangitis 13 8 4 4321 25 2024 10.3390/IJMS25084321 Guo Ziqi He Kun Pang Ke Yang Daiyu Lyu Chengzhen Xu Haifeng Wu Dong International Journal of Molecular Sciences 2024, Vol. 25, Page 4321 Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota–Bile Acid–Immunity Network 7 1 11 127-135 48 2021 10.1007/S00261-021-03335-X 10.1007/S00261-021-03335-X Morgan Matthew A. Sundaram Karthik M. Abdominal Radiology 2021 48:1 Primary biliary cholangitis: review for radiologists 1 SUPPL. 4 1 106-115 59 Suppl 4 1983 Scheuer P. J. Postgraduate Medical Journal Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. 7 4 1696121 13 2026 10.3389/FMED.2026.1696121 Wang Xiuhong Zhang Lina Liu Shixuan Zhang Tong Wang Tailing Zhong Dingrong Frontiers in Medicine Clinicopathological features of non-cirrhotic portal fibrosis in primary biliary cholangitis: a 15-year experience at a tertiary referral center 1 1 2 1-23 16 2022 10.1007/S12072-021-10276-6 10.1007/S12072-021-10276-6 You Hong Ma Xiong Efe Cumali Wang Guiqiang Jeong Sook Hyang Abe Kazumichi Duan Weijia Chen Sha Kong Yuanyuan Zhang Dong Wei Lai Wang Fu Sheng Lin Han Chieh Yang Jin Mo Tanwandee Tawesak Gani Rino A. Payawal Diana A. Sharma Barjesh C. Hou Jinlin Yokosuka Osamu Dokmeci A. Kadir Crawford Darrell Kao Jia Horng Piratvisuth Teerha Suh Dong Jin Lesmana Laurentius A. Sollano Jose Lau George Sarin Shiv K. Omata Masao Tanaka Atsushi Jia Jidong Springer APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis 3 736 11 2023 10.14218/JCTH.2022.00347 10.14218/JCTH.2022.00347 You Hong Duan Weijia Li Shuxiang Lv Tingting Chen Sha Lu Lungen Ma Xiong Han Ying Nan Yuemin Xu Xiaoyuan Duan Zhongping Wei Lai Jia Jidong Zhuang Hui Journal of Clinical and Translational Hepatology Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021) 1 1 7 145-172 67 2017 10.1016/J.JHEP.2017.03.022 10.1016/J.JHEP.2017.03.022 Hirschfield Gideon M. Beuers Ulrich Corpechot Christophe Invernizzi Pietro Jones David Marzioni Marco Schramm Christoph Journal of Hepatology EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis 27 8 8 1774 15 2023 10.4240/WJGS.V15.I8.1774 10.4240/WJGS.V15.I8.1774 Feng Juan Xu Jia-Min Fu Hai-Yan Xie Nan Bao Wei-Min Tang Ying-Mei World Journal of Gastrointestinal Surgery Prognostic scores in primary biliary cholangitis patients with advanced disease 1 3 3 930-950 63 2016 10.1002/HEP.28017;JOURNAL:JOURNAL:15273350;WGROUP:STRING:PUBLICATION 10.1002/HEP.28017;JOURNAL:JOURNAL:15273350;WGROUP:STRING:PUBLICATION Carbone Marco Sharp Stephen J. Flack Steve Paximadas Dimitrios Spiess Kelly Adgey Carolyn Griffiths Laura Lim Reyna Trembling Paul Williamson Kate Wareham Nick J. Aldersley Mark Bathgate Andrew Burroughs Andrew K. Heneghan Michael A. Neuberger James M. Thorburn Douglas Hirschfield Gideon M. Cordell Heather J. Alexander Graeme J. Jones David E.J. Sandford Richard N. Mells George F. Jones David Kirby John Alexander Graeme Sandford Richard Taylor-Robinson Simon Ch'ng Chin Lye Rahman Mesbah Yapp Tom Sturgess Richard Healey Christopher Czajkowski Marek Gunasekera Anton Gyawali Pranab Premchand Purushothaman Kapur Kapil Marley Richard Foster Graham Watson Alan Dias Aruna Subhani Javaid Harvey Rory McCorry Roger Ramanaden David Gasem Jaber Evans Richard Mathialahan Thiriloganathan Shorrock Christopher Lipscomb George Southern Paul Tibble Jeremy Gorard David Palegwala Altaf Jones Susan Dawwas Mohamed Dolwani Sunil Prince Martin Foxton Matthew Elphick David Mitchison Harriet Gooding Ian Karmo Mazn Saksena Sushma Mendall Mike Patel Minesh Ede Roland Austin Andrew Sayer Joanna Hankey Lorraine Hovell Christopher Fisher Neil Carter Martyn Koss Konrad Piotrowicz Andrzej Grimley Charles Neal David Lim Guan Levi Sass Ala Aftab Broad Andrea Saeed Athar Wood Gordon Brown Jonathan Wilkinson Mark Gordon Harriet Ramage John Ridpath Jo Ngatchu Theodore Grover Bob Shaukat Syed Shidrawi Ray Abouda George Ali Faiz Rees Ian Salam Imroz Narain Mark Brown Ashley Williams Simon Grellier Leonie Banim Paul Chilton Andrew Curtis Howard Gess Markus Drake Ian Davies Mervyn Jones Rebecca McNair Alastair Srirajaskanthan Raj Pitcher Maxton Sen Sambit Bird George Barnardo Adrian Kitchen Paul Yoong Kevin Chirag Oza Sivaramakrishnan Nurani MacFaul George Shah Amir Evans Chris Saha Subrata Pollock Katharine Bramley Peter Mukhopadhya Ashis Fraser Andrew Mills Peter Shallcross Christopher Campbell Stewart Shepherd Alan Dillon John Rushbrook Simon Przemioslo Robert Macdonald Christopher Metcalf Jane Shmueli Udi Davis Andrew Naqvi Asifabbas Lee Tom Ryder Stephen D. Collier Jane Klass Howard Ninkovic Mary Cramp Matthew Sharer Nicholas Aspinall Richard Goggin Patrick Ghosh Deb Douds Andrew Hoeroldt Barbara Booth Jonathan Williams Earl Hussaini Hyder Stableforth William Ayres Reuben Marshall Eileen Mann Steven Lombard Martin Richardson Paul Patanwala Imran Maltby Julia Brookes Matthew Mathew Ray Vyas Samir Singhal Saket Gleeson Dermot Misra Sharat Butterworth Jeff George Keith Harding Tim Douglass Andrew Panter Simon Shearman Jeremy Bray Gary Butcher Graham Forton Daniel Mclindon John Das Debashis Cowan Matthew Whatley Gregory Mandal Aditya Gupta Hemant Sanghi Pradeep Jain Sanjiv Pereira Steve Prasad Geeta Watts Gill Wright Mark Gordon Fiona Unitt Esther Grant Allister Delahooke Toby Higham Andrew Brind Alison Cox Mark Ramakrishnan Subramaniam King Alistair Collins Carole Whalley Simon Li Andy Fraser Jocelyn Bell Andrew Wong Voi Shim Singhal Amit Gee Ian Ang Yeng Ransford Rupert Gotto James Millson Charles Bowles Jane Thomas Caradog Harrison Melanie Galaska Roman Kendall Jennie Whiteman Jessica Lawlor Caroline Gray Catherine Elliott Keith Mulvaney-Jones Caroline Hobson Lucie Duyvenvoorde Greta Loftus Alison Seward Katie Penn Ruth Maiden Jane Damant Rose Hails Janeane Cloudsdale Rebecca Silvestre Valeria Glenn Sue Dungca Eleanor Wheatley Natalie Doyle Helen Kent Melanie Hamilton Caroline Braim Delyth Wooldridge Helen Abrahams Rachel Paton Alison Lancaster Nicola Gibbins Andrew Hogben Karen Desousa Phillipa Muscariu Florin Musselwhite Janine McKay Alexandra Tan Lai Ting Foale Carole Brighton Jacqueline Flahive Kerry Nambela Estelle Townshend Paula Ford Chris Holder Sophie Palmer Caroline Featherstone James Nasseri Mariam Sadeghian Joy Williams Bronwen Thomas Carol Rolls Sally Ann Hynes Abigail Duggan Claire Jones Sarah Crossey Mary Stansfield Glynis MacNicol Carolyn Wilkins Joy Wilhelmsen Elva Raymode Parizade Lee Hye Jeong Durant Emma Bishop Rebecca Ncube Noma Tripoli Sherill Casey Rebecca Cowley Caroline Miller Richard Houghton Kathryn Ducker Samantha Wright Fiona Bird Bridget Baxter Gwen Keggans Janie Hughes Maggie Grieve Emma Young Karin D. Williams Ocker Kate Hines Frances Martin Kirsty Innes Caron Valliani Talal Fairlamb Helen Thornthwaite Sarah Eastick Anne Tanqueray Elizabeth Morrison Jennifer Holbrook Becky Browning Julie Walker Kirsten Congreave Susan Verheyden Juliette Slininger Susan Stafford Lizzie Denise O'Donnell Ainsworth Mark Lord Susan Kent Linda March Linda Dickson Christine Simpson Diane Longhurst Beverley Hayes Maria Shpuza Ervin White Nikki Besley Sarah Pearson Sallyanne Wright Alice Jones Linda Gunter Emma Dewhurst Hannah Fouracres Anna Farrington Liz Graves Lyn Marriott Suzie Leoni Marina Tyrer David Martin Kate Dali-kemmery Lola Lambourne Victoria Green Marie Sirdefield Dawn Amor Kelly Colley Julie Shinder Bal Jones Jayne Mills Marisa Carnahan Mandy Taylor Natalie Boulton Kerenza Tregonning Julie Brown Carly Clifford Gayle Archer Emily Hamilton Maria Curtis Janette Shewan Tracey Walsh Sue Warner Karen Netherton Kimberley Mupudzi Mcdonald Gunson Bridget Gitahi Jane Gocher Denise Batham Sally Pateman Hilary Desmennu Senayon Conder Jill Clement Darren Gallagher Susan Orpe Jacky Chan Pui Ching Currie Lynn Lynn O'Donohoe Oblak Metod Morgan Lisa Quinn Marie Amey Isobel Baird Yolanda Cotterill Donna Cumlat Lourdes Winter Louise Greer Sandra Spurdle Katie Allison Joanna Dyer Simon Sweeting Helen Kordul Jean Hepatology The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis 1 7 12 1804-1812.e4 149 2015 10.1053/J.GASTRO.2015.07.061 10.1053/J.GASTRO.2015.07.061 Lammers Willem J. Hirschfield Gideon M. Corpechot Christophe Nevens Frederik Lindor Keith D. Janssen Harry L.A. Floreani Annarosa Ponsioen Cyriel Y. Mayo Marlyn J. Invernizzi Pietro Battezzati Pier M. Parés Albert Burroughs Andrew K. Mason Andrew L. Kowdley Kris Kumagi Teru Harms Maren H. Trivedi Palak J. Poupon Raoul Cheung Angela Lleo Ana Caballeria Llorenç Hansen Bettina E. Buuren Henk R. Gastroenterology Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy 1 1 1 394-419 69 2019 10.1002/HEP.30145 10.1002/HEP.30145 Lindor Keith D. Bowlus Christopher L. Boyer James Levy Cynthia Mayo Marlyn Hepatology Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases 1 6 1 707-713 20 1994 10.1016/S0168-8278(05)80139-4 10.1016/S0168-8278(05)80139-4 Mahl Thomas C. Shockcor William Boyer James L. Journal of Hepatology Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years 1 1 1 7831165 2022 2022 10.1155/2022/7831165 Mijic Maja Saric Ivona Delija Bozena Lalovac Milos Sobocan Nikola Radetic Eva Martincevic Dora Kanizaj Tajana Filipec Canadian Journal of Gastroenterology and Hepatology Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients 1 1 7 1-7 10 1989 10.1002/HEP.1840100102;PAGE:STRING:ARTICLE/CHAPTER 10.1002/HEP.1840100102;PAGE:STRING:ARTICLE/CHAPTER Dickson E. Rolland Grambsch Patricia M. Fleming Thomas R. Fisher Lloyd D. Langworthy Alice Hepatology Prognosis in primary biliary cirrhosis: Model for decision making 4 2 5 109-135 33 2018 10.1080/17498430.2018.1450055 Stalpers Lukas J.A. Kaplan Edward L. BSHM Bulletin: Journal of the British Society for the History of Mathematics Edward L. Kaplan and the Kaplan-Meier Survival Curve 17 5 8 3 2023 10.54724/LC.2023.E8 Lee Seung Won Life Cycle Kaplan-Meier and Cox proportional hazards regression in survival analysis: statistical standard and guideline of Life Cycle Committee 1 2 8 518-531 76 2022 10.1002/HEP.32405;WGROUP:STRING:PUBLICATION 10.1002/HEP.32405;WGROUP:STRING:PUBLICATION Mayo Marlyn J. Hepatology Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis? 1 3 9 572-581 75 2021 10.1016/J.JHEP.2021.04.055 10.1016/J.JHEP.2021.04.055 Cordell Heather J. Fryett James J. Ueno Kazuko Darlay Rebecca Aiba Yoshihiro Hitomi Yuki Kawashima Minae Nishida Nao Khor Seik Soon Gervais Olivier Kawai Yosuke Nagasaki Masao Tokunaga Katsushi Tang Ruqi Shi Yongyong Li Zhiqiang Juran Brian D. Atkinson Elizabeth J. Gerussi Alessio Carbone Marco Asselta Rosanna Cheung Angela Andrade Mariza Baras Aris Horowitz Julie Ferreira Manuel A.R. Sun Dylan Jones David E. Flack Steven Spicer Ann Mulcahy Victoria L. Byan Jinyoung Han Younghun Sandford Richard N. Lazaridis Konstantinos N. Amos Christopher I. Hirschfield Gideon M. Seldin Michael F. Invernizzi Pietro Siminovitch Katherine A. Ma Xiong Nakamura Minoru Mells George F. Mason Andrew Vincent Catherine Xie Gang Zhang Jinyi Affronti Andrea Almasio Piero L. Alvaro Domenico Andreone Pietro Andriulli Angelo Azzaroli Francesco Battezzati Pier Maria Benedetti Antonio Bragazzi Maria Consiglia Brunetto Maurizia Bruno Savino Calvaruso Vincenza Cardinale Vincenzo Casella Giovanni Cazzagon Nora Ciaccio Antonio Coco Barbara Colli Agostino Colloredo Guido Colombo Massimo Colombo Silvia Cristoferi Laura Cursaro Carmela Crocè Lory Saveria Crosignani Andrea D'Amato Daphne Donato Francesca Elia Gianfranco Fabris Luca Fagiuoli Stefano Ferrari Carlo Floreani Annarosa Galli Andrea Giannini Edoardo Grattagliano Ignazio Lampertico Pietro Lleo Ana Malinverno Federica Mancuso Clara Marra Fabio Marzioni Marco Massironi Sara Mattalia Alberto Miele Luca Milani Chiara Morini Lorenzo Morisco Filomena Muratori Luigi Muratori Paolo Niro Grazia A. O'Donnell Sarah Picciotto Antonio Portincasa Piero Rigamonti Cristina Ronca Vincenzo Rosina Floriano Spinzi Giancarlo Strazzabosco Mario Tarocchi Mirko Tiribelli Claudio Toniutto Pierluigi Valenti Luca Vinci Maria Zuin Massimo Nakamura Hitomi Abiru Seigo Nagaoka Shinya Komori Atsumasa Yatsuhashi Hiroshi Ishibashi Hiromi Ito Masahiro Migita Kiyoshi Ohira Hiromasa Katsushima Shinji Naganuma Atsushi Sugi Kazuhiro Komatsu Tatsuji Mannami Tomohiko Matsushita Kouki Yoshizawa Kaname Makita Fujio Nikami Toshiki Nishimura Hideo Kouno Hiroshi Kouno Hirotaka Ota Hajime Komura Takuya Nakamura Yoko Shimada Masaaki Hirashima Noboru Komeda Toshiki Ario Keisuke Nakamuta Makoto Yamashita Tsutomu Furuta Kiyoshi Kikuchi Masahiro Naeshiro Noriaki Takahashi Hironao Mano Yutaka Tsunematsu Seiji Yabuuchi Iwao Shimada Yusuke Yamauchi Kazuhiko Sugimoto Rie Sakai Hironori Mita Eiji Koda Masaharu Tsuruta Satoru Kamitsukasa Hiroshi Sato Takeaki Masaki Naohiko Kobata Tatsuro Fukushima Nobuyoshi Ohara Yukio Muro Toyokichi Takesaki Eiichi Takaki Hitoshi Yamamoto Tetsuo Kato Michio Nagaoki Yuko Hayashi Shigeki Ishida Jinya Watanabe Yukio Kobayashi Masakazu Koga Michiaki Saoshiro Takeo Yagura Michiyasu Hirata Keisuke Tanaka Atsushu Takikawa Hajime Zeniya Mikio Abe Masanori Onji Morikazu Kaneko Shuichi Honda Masao Arai Kuniaki Arinaga-Hino Teruko Hashimoto Etsuko Taniai Makiko Umemura Takeji Joshita Satoru Nakao Kazuhiko Ichikawa Tatsuki Shibata Hidetaka Yamagiwa Satoshi Seike Masataka Honda Koichi Sakisaka Shotaro Takeyama Yasuaki Harada Masaru Senju Michio Yokosuka Osamu Kanda Tatsuo Ueno Yoshiyuki Kikuchi Kentaro Ebinuma Hirotoshi Himoto Takashi Yasunami Michio Murata Kazumoto Mizokami Masashi Kawata Kazuhito Shimoda Shinji Miyake Yasuhiro Takaki Akinobu Yamamoto Kazuhide Hirano Katsuji Ichida Takafumi Ido Akio Tsubouchi Hirohito Chayama Kazuaki Harada Kenichi Nakanuma Yasuni Maehara Yoshihiko Taketomi Akinobu Shirabe Ken Soejima Yuji Mori Akira Yagi Shintaro Uemoto Shinji H Egawa Tanaka Tomohiro Yamashiki Noriyo Tamura Sumito Sugawara Yasuhiro Kokudo Norihiro Chalasani Naga Luketic Vel Odin Joseph Chopra Kapil Abecasis Goncalo Cantor Michael Coppola Giovanni Economides Aris Lotta Luca A. Overton John D. Reid Jeffrey G. Shuldiner Alan Beechert Christina Forsythe Caitlin Fuller Erin D. Gu Zhenhua Lattari Michael Lopez Alexander Schleicher Thomas D. Padilla Maria Sotiropoulos Toledo Karina Widom Louis Wolf Sarah E. Pradhan Manasi Manoochehri Kia Ulloa Ricardo H. Bai Xiaodong Balasubramanian Suganthi Barnard Leland Blumenfeld Andrew Eom Gisu Habegger Lukas Hawes Alicia Khalid Shareef Maxwell Evan K. Salerno William Staples Jeffrey C. Jones Marcus B. Mitnaul Lyndon J. Sturgess Richard Healey Christopher Yeoman Andrew Gunasekera Anton VJ Kooner Paul Kapur Kapil Sathyanarayana V. Kallis Yiannis Subhani Javaid Harvey Rory McCorry Roger Rooney Paul Ramanaden David Evans Richard Mathialahan Thiriloganathan Gasem Jaber Shorrock Christopher Bhalme Mahesh Southern Paul Tibble Jeremy A. Gorard David A. Jones Susan Mells George Mulcahy Victoria Srivastava Brijesh Foxton Matthew R. Collins Carole E. Elphick David Karmo Mazn Porras-Perez Francisco Mendall Michael Yapp Tom Patel Minesh Ede Roland Sayer Joanne Jupp James Fisher Neil Carter Martyn J. Koss Konrad Shah Jayshri Piotrowicz Andrzej Scott Glyn Grimley Charles Gooding Ian R. Williams Simon Tidbury Judith Lim Guan Cheent Kuldeep Levi Sass Mansour Dina Beckley Matilda Hollywood Coral Wong Terry Marley Richard Ramage John Gordon Harriet M. Ridpath Jo Ngatchu Theodore Bob Grover Vijay Paul Shidrawi Ray G. Abouda George Corless L. Narain Mark Rees Ian Brown Ashley Taylor-Robinson Simon Wilkins Joy Grellier Leonie Banim Paul Das Debasish Heneghan Michael A. Curtis Howard Matthews Helen C. Mohammed Faiyaz Aldersley Mark Srirajaskanthan Raj Walker Giles McNair Alistair Sharif Amar Sen Sambit Bird George Prince Martin I. Prasad Geeta Kitchen Paul Barnardo Adrian Oza Chirag Sivaramakrishnan Nurani N. Gupta Prakash Shah Amir Evans Chris DJ Saha Subrata Pollock Katharine Bramley Peter Mukhopadhya Ashis Barclay Stephen T. McDonald Natasha Bathgate Andrew J. Palmer Kelvin Dillon John F. Rushbrook Simon M. Przemioslo Robert McDonald Chris Millar Andrew Tai Cheh Mitchell Stephen Metcalf Jane Shaukat Syed Ninkovic Mary Shmueli Udi Davis Andrew Naqvi Asifabbas Lee Tom JW Ryder Stephen Collier Jane Klass Howard Cramp Matthew E. Sharer Nichols Aspinall Richard Ghosh Deb Douds Andrew C. Booth Jonathan Williams Earl Hussaini Hyder Christie John Mann Steven Thorburn Douglas Marshall Aileen Patanwala Imran Ala Aftab Maltby Julia Matthew Ray Corbett Chris Vyas Sam Singhal Saket Gleeson Dermot Misra Sharat Butterworth Jeff George Keith Harding Tim Douglass Andrew Mitchison Harriet Panter Simon Shearman Jeremy Bray Gary Roberts Michael Butcher Graham Forton Daniel Mahmood Zahid Cowan Matthew Das Debashis Ch'ng Chin Lye Rahman Mesbah Whatley Gregory C.A. Wesley Emma Mandal Aditya Jain Sanjiv Pereira Stephen P. Wright Mark Trivedi Palak Gordon Fiona H. Unitt Esther Palejwala Altaf Austin Andrew Vemala Vishwaraj Grant Allister Higham Andrew D. Brind Alison Mathew Ray Cox Mark Ramakrishnan Subramaniam King Alistair Whalley Simon Fraser Jocelyn Thomson S. J. Bell Andrew Wong Voi Shim Kia Richard Gee Ian Keld Richard Ransford Rupert Gotto James Millson Charles Journal of Hepatology An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 6 1 1 1-7 308 1983 10.1056/NEJM198301063080101 10.1056/NEJM198301063080101 Roll Joseph Boyer James L. Barry Daniel Klatskin Gerald New England Journal of Medicine The Prognostic Importance of Clinical and Histologic Features in Asymptomatic and Symptomatic Primary Biliary Cirrhosis 11 2 12 99-110 57 2021 10.1007/S00535-021-01839-3 10.1007/S00535-021-01839-3 Burghart Lukas Halilbasic Emina Schwabl Philipp Simbrunner Benedikt Stättermayer Albert Friedrich Petrenko Oleksandr Scheiner Bernhard Bauer David Pinter Matthias Boztug Kaan Mandorfer Mattias Trauner Michael Reiberger Thomas Journal of Gastroenterology 2021 57:2 Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis 1 17 9 5713 12 2023 10.3390/JCM12175713 Martini Francesco Balducci Daniele Mancinelli Martina Buzzanca Valerio Fracchia Elena Tarantino Giuseppe Benedetti Antonio Marzioni Marco Maroni Luca Journal of Clinical Medicine 2023, Vol. 12, Page 5713 Risk Stratification in Primary Biliary Cholangitis Trivedi PJ Gut GM Hirschfield - 2021 undefined gut.bmj.comPJ Trivedi, GM HirschfieldGut, 2021•gut.bmj.com Recent advances in clinical practice: epidemiology of autoimmune liver diseases 1 2 8 879-891 74 2021 10.1002/HEP.31776 10.1002/HEP.31776 John Binu Aitcheson Gabriella Schwartz Kaley B. Khakoo Nidah S. Dahman Bassam Deng Yangyang Goldberg David Martin Paul Taddei Tamar H. Levy Cynthia Kaplan David E. Hepatology Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis 12 3 1534145 4 2025 10.3389/FGSTR.2025.1534145/TEXT Liu Yaxing Gao Muyu Li Bin Liu Long Liu Yao Feng Ying Wang Xiaojing Wang Xianbo Zhou Guiqin Frontiers in Gastroenterology Risk factors for mortality in patients with primary biliary cholangitis: a nomogram to predict 5-year survival 1 61 21 2024 10.7150/IJMS.88481 10.7150/IJMS.88481 Fu Xin Yu Song Ya Qi Lin Jia Ying Wang Yi Wu Wei Dan Peng Jin Bang Ye Li Ping Chen Kai Li Shao Wei International Journal of Medical Sciences Developing a Prognostic Model for Primary Biliary Cholangitis Based on a Random Survival Forest Model 1 11 6 1775-1784 61 2025 10.1111/APT.70120;SUBPAGE:STRING:FULL 10.1111/APT.70120;SUBPAGE:STRING:FULL Kowdley Kris Victor David W. MacEwan Joanna P. Nair Radhika Levine Alina Hernandez Jennifer Bessonova Leona Li Jing Wheeler Darren Hirschfield Gideon Alimentary Pharmacology and Therapeutics Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population-Based Study 1 1 9 29 2024 10.4103/JRMS.JRMS_813_22 Javad Sajadi Sayed Mohammad Tamizifar Babak Sanei Mohammad Hossein Babak Anahita Journal of Research in Medical Sciences Factors associated with progression and outcomes of primary biliary cholangitis: A cohort study, 2010-2019 1 3 3 265-272 49 2025 10.1097/PAS.0000000000002343 10.1097/PAS.0000000000002343 Yu Haitian Lv Tingting Li Shuxiang Chen Sha Li Min Liu Jimin Duan Weijia Jia Jidong Zhao Xinyan American Journal of Surgical Pathology Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis with Ductopenia 1 1 1 5557814 2021 2021 10.1155/2021/5557814 10.1155/2021/5557814 Liu Yuwei Han Kai Liu Chen Duan Fangfang Cheng Jun Yang Song Canadian Journal of Gastroenterology and Hepatology Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study 1 4 10 1044-1051 123 2002 10.1053/GAST.2002.36027 10.1053/GAST.2002.36027 Prince Martin Chetwynd Amanda Newman Wendy Metcalf Jane James Oliver F.W. Gastroenterology Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years 1 3 3 715-720 130 2006 10.1053/J.GASTRO.2005.12.029 10.1053/J.GASTRO.2005.12.029 Parés Albert Caballería Llorenç Rodés Juan Gastroenterology Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid 1 5 5 1207-1216 94 1988 10.1016/0016-5085(88)90014-5 10.1016/0016-5085(88)90014-5 Esquivel Carlos O. Thiel David H. Demetris Anthony J. Bernardos Angel Iwatsuki Shunzaburo Markus Bernd Gordon Robert D. Marsh J. Wallis Makowka Leonard Tzakis Andreas G. Todo Satoru Gavaler Judith S. Starzl Thomas E. Gastroenterology Transplantation for primary biliary cirrhosis